한글목차

세계의 골다공증 치료제 시장 규모는 2019년에 114억 3,616만 달러에 달했습니다. 이 시장은 2024년까지 CAGR 2.00% 이상으로 성장하고 있습니다.

실적 기간 중 건강 보험의 확대는 골다공증 치료제 시장의 성장을 지원했습니다. 건강 보험은 의료 비용을 절감하고 골다공증 치료제의 구매 용이성과 접근성을 향상시킵니다. 생물제제 및 주사제와 같은 첨단 치료제에 대한 보험 적용은 환자 도입을 촉진하여 시장 성장을 지원합니다. 보험은 경제적 장벽을 완화함으로써 적시에 진단과 치료를 촉진하고, 혁신적인 골다공증 치료제에 대한 수요를 촉진하여 시장 잠재력을 확대합니다. 예를 들어 인도의 온라인 보험 애그리게이터이자 핀테크 플랫폼인 PolicyBazaar에 따르면 인도에서 정기보험에 가입하는 여성의 수가 크게 증가하여 지난 2년 동안 80% 증가했다고 합니다. 또한 스위스 리에 따르면 2023-24년 보험 보급률은 인도에서 3.8%, 전 세계에서 6.5%를 나타낼 것으로 예측됩니다. 따라서 의료보험의 확대가 골다공증 치료제 시장의 성장을 촉진했습니다.

세계의 골다공증 치료제 시장에 대해 조사했으며, 시장의 개요와 유형별, 투여 방법별, 유통 채널별, 용도별, 지역·국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 개요

제2장 목차

제3장 표 리스트

제4장 도표

제5장 리포트 구성

제6장 시장의 특징

• 일반적인 시장의 정의
• 요약
• 골다공증 치료제 시장의 정의와 세분화
• 유형별 시장 세분화
  • 비스포스포네이트
  • 선택적 에스트로겐 수용체 모듈레이터(SERM)
  • RANK 리간드 저해제
  • 부갑상선 호르몬 요법
  • 칼시토닌
  • 스클레로스틴 저해제
  • 기타
• 투여 방법별 시장 세분화
  • 경구
  • 주사
• 유통 채널별 시장 세분화
  • 소매 약국
  • 병원 약국
  • 온라인 판매
• 용도별 시장 세분화
  • 원발성 골다공증
  • 연발성 골다공증

제7장 주요 시장 동향

• 환자 결과를 개선하는 혁신적인 골다공증 치료가 발매
• 혁신적인 어프로치와 규제기관의 승인이 치료의 진보를 추진
• 골다공증 치료의 개선을 향한 표적 치료 옵션별 첨단 치료

제8장 골다공증 치료제 시장 - 거시경제 시나리오

제9장 세계 시장 규모와 성장

• 시장 규모
• 시장 성장 실적, 2019-2024년
• 시장 성장 예측, 2024-2029년, 2034년

제10장 세계의 골다공증 치료제 시장 세분화

• 세계의 골다공증 치료제 시장, 유형별 세분화, 실적 및 예측, 2019-2024년, 2029년 예측, 2034년 예측
• 세계의 골다공증 치료제 시장, 투여법별 세분화, 실적 및 예측, 2019-2024년, 2029년, 2034년
• 세계의 골다공증 치료제 시장, 유통 채널별 세분화, 실적 및 예측, 2019-2024년, 2029년 예측, 2034년 예측
• 세계의 골다공증 치료제 시장, 용도별 세분화, 실적 및 예측, 2019-2024년, 2029년 예측, 2034년 예측

제11장 골다공증 치료제 시장, 지역별·국가별 분석

• 세계의 골다공증 치료제 시장, 지역별, 실적 및 예측, 2019-2024년, 2029년 예측, 2034년 예측
• 세계의 골다공증 치료제 시장, 국가별, 실적 및 예측, 2019-2024년, 2029년 예상, 2034년 예상

제12장 아시아태평양 시장

제13장 서유럽 시장

제14장 동유럽 시장

제15장 북미 시장

제16장 남미 시장

제17장 중동 시장

제18장 아프리카 시장

제19장 경쟁 구도와 기업 개요

• 기업 개요
• Amgen Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Eisai Co., Ltd.
• Apotex Inc.

제20장 기타 대기업과 혁신적 기업

• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• GSK plc
• Daiichi Sankyo Company, Limited
• F. Hoffmann La Roche Ltd.
• Teva Pharmaceutical Industries Limited
• Merck & Co. Inc.
• Radius Health, Inc.
• Mylan N.V.(Viatris)
• Sun Pharmaceutical Industries Ltd.
• UCB Biopharma SRL
• Dr. Reddy's Laboratories
• Strides Pharma Science Limited
• EffRx Pharmaceuticals SA

제21장 경쟁 벤치마킹

제22장 경쟁 대시보드

제23장 주요 합병과 인수

제24장 기회와 전략

• 2029년의 세계 골다공증 치료제 시장 - 가장 새로운 기회를 제공하는 국가
• 2029년의 세계 골다공증 치료제 시장 - 가장 새로운 기회를 제공하는 부문
• 2029년의 세계 골다공증 치료제 시장 - 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제25장 골다공증 치료제 시장, 결론·제안

제26장 부록

영문목차

Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis-a condition characterized by decreased bone density and increased susceptibility to fractures. The primary goal of these medications is to strengthen bones, reduce bone loss and lower the risk of fractures.

The osteoporosis drugs market consists of sales, by entities (organizations, sole traders, or partnerships), of osteoporosis drugs that are primarily used by individuals diagnosed with osteoporosis, including postmenopausal women, older adults and patients undergoing treatments that affect bone density, such as long-term corticosteroid therapy.

The global osteoporosis drugs market was valued at $11,436.16 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 2.00%.

Health Insurance Expansion

During the historic period, the health insurance expansion supported the growth of the osteoporosis drugs market. Health insurance reduces healthcare costs, increasing affordability and access to osteoporosis medications. Coverage for advanced treatments, such as biologics and injectables, incentivizes patient adoption and supports market growth. By alleviating financial barriers, insurance encourages timely diagnosis and treatment, driving demand for innovative osteoporosis therapies and expanding their market potential. For example, according to PolicyBazaar, an Indian online insurance aggregator and fintech platform, the number of women purchasing term insurance plans in India has witnessed significant growth, with an 80% increase over the past two years. Additionally, insurance penetration in 2023-24 is projected to reach 3.8% in India and 6.5% globally according to Swiss Re. Therefore, the health insurance expansion drove the growth of the osteoporosis drugs market.

Innovative Approaches And Regulatory Approvals Driving Treatment Advancements

Companies in the osteoporosis drugs market are prioritizing the development of innovative solutions, such as obtaining regulatory approvals to enhance treatment outcomes. Regulatory approvals refer to official authorization from health agencies, ensuring new treatments meet safety, efficacy and quality standards before market release. For instance, in November 2024, Teva Pharmaceuticals Inc., a US-based pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for generic version of Forteo (teriparatide injection). This generic medication is recommended for postmenopausal women with osteoporosis at high fracture risk who are unable to use alternative treatments. It is also suitable for men with primary or hypogonadal osteoporosis under similar conditions. Additionally, it applies to both men and women experiencing osteoporosis due to long-term glucocorticoid use, again at high fracture risk and unable to use alternative therapies.

The global osteoporosis drugs market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 39.7% of the total market in 2023.

Osteoporosis Drugs Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global osteoporosis drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for osteoporosis drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider osteoporosis drugs market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by administration, by distribution channel and by application.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the osteoporosis drugs market.
• Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by administration, by distribution channel and by application in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for osteoporosis drugs providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors; Parathyroid Hormone Therapy; Calcitonin; Sclerostin Inhibitor; Other Drug Class
• 2) By Administration: Oral; Injectable
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
• 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
• Companies Mentioned: Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Eisai Co., Ltd.; Apotex Inc.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; osteoporosis drugs indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Osteoporosis Drugs - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Osteoporosis Drugs Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Bisphosphonates
  • 6.4.2 Selective Estrogen Receptor Modulators (SERMs)
  • 6.4.3 RANK Ligand Inhibitors
  • 6.4.4 Parathyroid Hormone Therapy
  • 6.4.5 Calcitonin
  • 6.4.6 Sclerostin Inhibitor
  • 6.4.7 Other Drug Class
• 6.5 Market Segmentation By Administration
  • 6.5.1 Oral
  • 6.5.2 Injectable
• 6.6 Market Segmentation By Distribution Channel
  • 6.6.1 Retail Pharmacies
  • 6.6.2 Hospital Pharmacies
  • 6.6.3 Online Sales
• 6.7 Market Segmentation By Application
  • 6.7.1 Primary Osteoporosis
  • 6.7.2 Secondary Osteoporosis

7 Major Market Trends

• 7.1 Innovative Osteoporosis Treatment Launched To Enhance Patient Outcomes
• 7.2 Innovative Approaches And Regulatory Approvals Driving Treatment Advancements
• 7.3 Advance Treatment With Targeted Therapeutic Option For Better Osteoporosis Treatment

8 Osteoporosis Drugs Market - Macro Economic Scenario

• 8.1 COVID-19 Impact On The Osteoporosis Drugs Market
• 8.2 Impact Of The War In Ukraine On The Osteoporosis Drugs Market
• 8.3 Impact Of High Inflation On The Osteoporosis Drugs Market

9 Global Market Size and Growth

• 9.1 Market Size
• 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 9.2.1 Market Drivers 2019 - 2024
  • 9.2.2 Market Restraints 2019 - 2024
• 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 9.3.1 Market Drivers 2024 - 2029
  • 9.3.2 Market Restraints 2024 - 2029

10 Global Osteoporosis Drugs Market Segmentation

• 10.1 Global Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Osteoporosis Drugs Market, Segmentation By Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.3 Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.4 Global Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Osteoporosis Drugs Market, Regional and Country Analysis

• 11.1 Global Osteoporosis Drugs Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.2 Global Osteoporosis Drugs Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

• 12.1 Summary
  • 12.1.1 Market Overview
  • 12.1.2 Region Information
  • 12.1.3 Market Information
  • 12.1.4 Background Information
  • 12.1.5 Government Initiatives
  • 12.1.6 Regulations
  • 12.1.7 Regulatory Bodies
  • 12.1.8 Major Associations
  • 12.1.9 Taxes Levied
  • 12.1.10 Corporate Tax Structure
  • 12.1.11 Investments
  • 12.1.12 Major Companies
• 12.2 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.3 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Asia-Pacific Osteoporosis Drugs Market: Country Analysis
• 12.6 China Market
• 12.7 Summary
  • 12.7.1 Market Overview
  • 12.7.2 Country Information
  • 12.7.3 Market Information
  • 12.7.4 Background Information
  • 12.7.5 Government Initiatives
  • 12.7.6 Regulations
  • 12.7.7 Regulatory Bodies
  • 12.7.8 Major Associations
  • 12.7.9 Taxes Levied
  • 12.7.10 Corporate Tax Structure
  • 12.7.11 Investments
  • 12.7.12 Major Companies
• 12.8 China Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 China Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 India Market
• 12.12 India Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 India Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 Japan Market
• 12.16 Japan Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 Japan Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Australia Market
• 12.20 Australia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Australia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Indonesia Market
• 12.24 Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Indonesia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.27 South Korea Market
• 12.28 South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.29 South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.30 South Korea Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

• 13.1 Summary
  • 13.1.1 Market Overview
  • 13.1.2 Region Information
  • 13.1.3 Market Information
  • 13.1.4 Background Information
  • 13.1.5 Government Initiatives
  • 13.1.6 Regulations
  • 13.1.7 Regulatory Bodies
  • 13.1.8 Major Associations
  • 13.1.9 Taxes Levied
  • 13.1.10 Corporate tax structure
  • 13.1.11 Investments
  • 13.1.12 Major Companies
• 13.2 Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.3 Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Western Europe Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Western Europe Osteoporosis Drugs Market: Country Analysis
• 13.6 UK Market
• 13.7 UK Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.8 UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 UK Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 Germany Market
• 13.11 Germany Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.12 Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.13 Germany Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.14 France Market
• 13.15 France Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.16 France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.17 France Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.18 Italy Market
• 13.19 Italy Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.20 Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.21 Italy Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.22 Spain Market
• 13.23 Spain Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.24 Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.25 Spain Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

• 14.1 Summary
  • 14.1.1 Market Overview
  • 14.1.2 Region Information
  • 14.1.3 Market Information
  • 14.1.4 Background Information
  • 14.1.5 Government Initiatives
  • 14.1.6 Regulations
  • 14.1.7 Regulatory Bodies
  • 14.1.8 Major Associations
  • 14.1.9 Taxes Levied
  • 14.1.10 Corporate Tax Structure
  • 14.1.11 Investments
  • 14.1.12 Major companies
• 14.2 Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.3 Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 Eastern Europe Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 Eastern Europe Osteoporosis Drugs Market: Country Analysis
• 14.6 Russia Market
• 14.7 Russia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.8 Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.9 Russia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

• 15.1 Summary
  • 15.1.1 Market Overview
  • 15.1.2 Region Information
  • 15.1.3 Market Information
  • 15.1.4 Background Information
  • 15.1.5 Government Initiatives
  • 15.1.6 Regulations
  • 15.1.7 Regulatory Bodies
  • 15.1.8 Major Associations
  • 15.1.9 Taxes Levied
  • 15.1.10 Corporate Tax Structure
  • 15.1.11 Investments
  • 15.1.12 Major Companies
• 15.2 North America Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.3 North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 North America Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 North America Osteoporosis Drugs Market: Country Analysis
• 15.6 USA Market
• 15.7 Summary
  • 15.7.1 Market Overview
  • 15.7.2 Country Information
  • 15.7.3 Market Information
  • 15.7.4 Background Information
  • 15.7.5 Government Initiatives
  • 15.7.6 Regulations
  • 15.7.7 Regulatory Bodies
  • 15.7.8 Major Associations
  • 15.7.9 Taxes Levied
  • 15.7.10 Corporate Tax Structure
  • 15.7.11 Investments
  • 15.7.12 Major Companies
• 15.8 USA Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.10 USA Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.11 Canada Market
• 15.12 Canada Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.13 Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.14 Canada Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

• 16.1 Summary
  • 16.1.1 Market Overview
  • 16.1.2 Region Information
  • 16.1.3 Market Information
  • 16.1.4 Background Information
  • 16.1.5 Government Initiatives
  • 16.1.6 Regulations
  • 16.1.7 Regulatory Bodies
  • 16.1.8 Major Associations
  • 16.1.9 Taxes Levied
  • 16.1.10 Corporate Tax Structure
  • 16.1.11 Investments
  • 16.1.12 Major Companies
• 16.2 South America Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.3 South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 South America Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Brazil Market
• 16.6 Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.7 Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.8 Brazil Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

• 17.1 Summary
  • 17.1.1 Market Overview
  • 17.1.2 Region Information
  • 17.1.3 Market Information
  • 17.1.4 Background Information
  • 17.1.5 Government Initiatives
  • 17.1.6 Regulations
  • 17.1.7 Regulatory Bodies
  • 17.1.8 Major Associations
  • 17.1.9 Taxes Levied
  • 17.1.10 Corporate Tax Structure
  • 17.1.11 Investments
  • 17.1.12 Major Companies
• 17.2 Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.3 Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Middle East Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

• 18.1 Summary
  • 18.1.1 Market Overview
  • 18.1.2 Region Information
  • 18.1.3 Market Information
  • 18.1.4 Background Information
  • 18.1.5 Government Initiatives
  • 18.1.6 Regulations
  • 18.1.7 Regulatory Bodies
  • 18.1.8 Major Associations
  • 18.1.9 Taxes Levied
  • 18.1.10 Corporate Tax Structure
  • 18.1.11 Investments
  • 18.1.12 Major Companies
• 18.2 Africa Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.3 Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.4 Africa Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape And Company Profiles

• 19.1 Company Profiles
• 19.2 Amgen Inc.
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
  • 19.2.3 Financial Overview
• 19.3 Eli Lilly and Company
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
  • 19.3.3 Financial Overview
• 19.4 Pfizer Inc.
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
  • 19.4.3 Financial Overview
• 19.5 Eisai Co., Ltd.
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
  • 19.5.3 Financial Overview
• 19.6 Apotex Inc.
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
  • 19.6.3 Business Strategy
  • 19.6.4 Financial Overview

20 Other Major And Innovative Companies

• 20.1 AbbVie Inc.
  • 20.1.1 Company Overview
  • 20.1.2 Products And Services
• 20.2 Novartis AG
  • 20.2.1 Company Overview
  • 20.2.2 Products And Services
• 20.3 Sanofi S.A.
  • 20.3.1 Company Overview
  • 20.3.2 Products And Services
• 20.4 GSK plc
  • 20.4.1 Company Overview
  • 20.4.2 Products And Services
• 20.5 Daiichi Sankyo Company, Limited
  • 20.5.1 Company Overview
  • 20.5.2 Products And Services
• 20.6 F. Hoffmann La Roche Ltd.
  • 20.6.1 Company Overview
  • 20.6.2 Products And Services
• 20.7 Teva Pharmaceutical Industries Limited
  • 20.7.1 Company Overview
  • 20.7.2 Products And Services
• 20.8 Merck & Co. Inc.
  • 20.8.1 Company Overview
  • 20.8.2 Products And Services
• 20.9 Radius Health, Inc.
  • 20.9.1 Company Overview
  • 20.9.2 Products And Services
• 20.10 Mylan N.V. (Viatris)
  • 20.10.1 Company Overview
  • 20.10.2 Products And Services
• 20.11 Sun Pharmaceutical Industries Ltd.
  • 20.11.1 Company Overview
  • 20.11.2 Products And Services
• 20.12 UCB Biopharma SRL
  • 20.12.1 Company Overview
  • 20.12.2 Products And Services
• 20.13 Dr. Reddy's Laboratories
  • 20.13.1 Company Overview
  • 20.13.2 Products And Services
• 20.14 Strides Pharma Science Limited
  • 20.14.1 Company Overview
  • 20.14.2 Products And Services
• 20.15 EffRx Pharmaceuticals SA
  • 20.15.1 Company Overview
  • 20.15.2 Products And Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

• 23.1 Bone Health Technologies Acquired Wellen
• 23.2 Nestle Health Science Acquired Bountiful Company

24 Opportunities And Strategies

• 24.1 Global Osteoporosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 24.2 Global Osteoporosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 24.3 Global Osteoporosis Drugs Market In 2029 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 Osteoporosis Drugs Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer